TOP10 reimbursement value in Poland

NHF spending on medical products, foodstuffs and medical devices reimbursement from January till February 2021 amounted to PLN 2.09 billion, including PLN 1.37 billion expenditures on products from outpatients list, PLN 0.65 billion from drug programmes and PLN 0.07 billion from chemotherapy.

NHF spending on TOP10 products with highest reimbursement value came to PLN 312 million, which is about 15% of total NHF expenditure on reimbursement from this period. On the TOP 10 are 6 medical products from drug programmes and 4 from outpatients list. Spinraza had the highest reimbursement value in the first 2 months of 2021, reimbursed in drug programmes.

Interestingly, in chemotherapy the 2nd in the ranking is Riximyo, the rituximab biosimilar. In contrast, the original drug MabThera is 7th on the list. Aranesp is the 1st on the ranking. Expenditure on the 10 drugs with the highest reimbursement amount accounted for 56% of the public payer’s on all drugs from chemotherapy.

Check out our miniIDA report.

More about IDA: